This trial is evaluating whether Cetuximab will improve 1 primary outcome and 1 secondary outcome in patients with Colorectal Cancer. Measurement will happen over the course of PFS will be measured from the date of first dose of study drug until first documented clinical or radiographic evidence of disease progression by RECIST 1.1, clinical progression, start of new therapy or death. Estimated assessment at 6 months..
This trial requires 21 total participants across 1 different treatment group
This trial involves a single treatment. Cetuximab is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"The most important features of CRC are anemia, anorexia, abdominal pain, constipation and weight loss. Rectal bleeding may be an important sign, and colonic bleeding should be considered a risk factor for CRC." - Anonymous Online Contributor
"Mutations in APC, COI1, hMSH3, p73, p53, SHH, and EGFR are involved in colorectal carcinogenesis. There have also been studies suggesting that a combination of these mutations may be responsible for the development of colorectal carcinoma.\n" - Anonymous Online Contributor
"Results from a recent clinical trial has suggested that cancer can be cured. The cure rate for patients diagnosed in localized or early stages is very high, and those patients with long-term survival. The cure rate for advanced cancers is relatively low, and those with long-term disease-free survival are uncommon." - Anonymous Online Contributor
"About 4% of all US [colon cancer](https://www.withpower.com/clinical-trials/colon-cancer)s occur in people who had a family history of cancer. On average, a person has 1.8 family members with a history of cancer: a parent, sibling, spouse, or childhood friend." - Anonymous Online Contributor
"Of the 3717,898 new diagnoses of CRC made in the first day of 2014, 44,914, or 1.15% of these cases, would be considered cases of invasive colorectal cancers, while the remaining cases would be adenocarcinoma of the noninvasive type. Therefore, assuming the majority of noninvasive colon cancer is due to an increase in use of colonoscopy and early detection efforts, it is possible to estimate the annual incidence of noninvasive-type colon cancer annually in the United States: 3.5 - 5." - Anonymous Online Contributor
"There might be some possible beneficial treatments for colorectal cancer. For example, treatment with interferon plus 5-fluoroorouracil plus leucovorin or 5-fluorouracil plus mitomycin C are possible benefits for CRC patients." - Anonymous Online Contributor
"Results from a recent clinical trial from the latest clinical trial showed that cetuximab was indeed effective for the treatment of CRC. However, the results of a previous clinical trial on its efficacy and tolerability is limited due to the use of an unconventional chemotherapy, FOLFIC. Therefore, the results of future trials of cetuximab in combination with conventional chemotherapy will play an important role." - Anonymous Online Contributor
"The survival rate for colorectal carcinoma (crc) is about 7 years. The five-year survival rate for crc is about 55 percent, and a five-year survival rate of 50 percent occurs in the elderly. At age 65, the survival rate for crc is about 70 percent. When left untreated, 50 percent of people with crc die within 10 years. However, if the cancer is checked regularly and if it is curable, survival is about 20 years in the United States from the time of its diagnosis. Also, if it isn't cured, the survival rates are about 65 percent, and the median survival time is about seven years." - Anonymous Online Contributor
"Since risk factors for CRC, that can be altered through lifestyle changes, are quite common, it is possible that CRC will be prevented through these changes. At this juncture, there is no evidence to show that CRC will be prevented by either the consumption of red or dark colored meat, or the overall amount of red meat consumed. The consumption of processed meat has no effect on the occurrence of CRC for men, but this does affect the occurrence of CRC in women. The type of meat consumed, the frequency of its intake, has no impact on the likelihood of CRC occurring, though it can reduce the risk of getting CRC on average." - Anonymous Online Contributor
"No common side effects were seen in patients receiving cetuximab; they were generally associated with the concurrent use of capecitabine and the concurrent use of cetuximab+capecitabine with or without bevacizumab, and occurred in both cohorts (P=0.4). They included constipation in 20% of patients receiving capecitabine alone, and fatigue, diarrhea, nausea, vomiting, dehydration, chest pain, dyspnea, peripheral edema, and hypotension in patients receiving cetuximab-capecitabine. Fatigue was also seen in patients receiving capecitabine + bevacizumab with or without cetuximab." - Anonymous Online Contributor
"This is one of the deadliest cancers. It is classified into sub-groups based on staging, and is treated according to the TNM staging system. The ultimate endpoint of all colorectal cancer staging systems is patient survival. [Power to detect and quantify changes in survival rate between the different staging groups in CRC are available from http://www.withpower.com/clinical-trials]." - Anonymous Online Contributor
"The inclusion criteria for clinical trials are different from the criteria used for clinical practice. Patients who meet these criteria may be considered for a clinical trial by the medical team." - Anonymous Online Contributor